Performance of electrochemical immunoassays for clinical diagnostics of SARS-CoV-2 based on selective nucleocapsid N protein detection: Boron-doped diamond, gold and glassy carbon evaluation

Wioleta Białobrzeska, Mateusz Ficek, Bartłomiej Dec, Silvio Osella, Bartosz Trzaskowski, Andres Jaramillo-Botero, Mattia Pierpaoli, Michał Rycewicz, Yanina Dashkevich, Tomasz Łęga, Natalia Malinowska, Zofia Cebula, Daniel Bigus, Daniel Firganek, Ewelina Bięga, Karolina Dziąbowska, Mateusz Brodowski, Marcin Kowalski, Mirosława Panasiuk, Beata GromadzkaSabina Żołędowska, Dawid Nidzworski, Krzysztof Pyrć, William A. Goddard, Robert Bogdanowicz

Producción: Contribución a una revistaArtículorevisión exhaustiva

36 Citas (Scopus)

Resumen

The 21st century has already brought us a plethora of new threats related to viruses that emerge in humans after zoonotic transmission or drastically change their geographic distribution or prevalence. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first spotted at the end of 2019 to rapidly spread in southwest Asia and later cause a global pandemic, which paralyzes the world since then. We have designed novel immunosensors targeting conserved protein sequences of the N protein of SARS-CoV-2 based on lab-produced and purified anti-SARS-CoV-2 nucleocapsid antibodies that are densely grafted onto various surfaces (diamond/gold/glassy carbon). Titration of antibodies shows very strong reactions up to 1:72 900 dilution. Next, we showed the mechanism of interactions of our immunoassay with nucleocapsid N protein revealing molecular recognition by impedimetric measurements supported by hybrid modeling results with both density functional theory and molecular dynamics methods. Biosensors allowed for a fast (in less than 10 min) detection of SARS-CoV-2 virus with a limit of detection from 0.227 ng/ml through 0.334 ng/ml to 0.362 ng/ml for glassy carbon, boron-doped diamond, and gold surfaces, respectively. For all tested surfaces, we obtained a wide linear range of concentrations from 4.4 ng/ml to 4.4 pg/ml. Furthermore, our sensor leads to a highly specific response to SARS-CoV-2 clinical samples versus other upper respiratory tract viruses such as influenza, respiratory syncytial virus, or Epstein-Barr virus. All clinical samples were tested simultaneously on biosensors and real-time polymerase chain reactions.

Idioma originalInglés
Número de artículo114222
PublicaciónBiosensors and Bioelectronics
Volumen209
DOI
EstadoPublicada - 01 ago. 2022
Publicado de forma externa

Huella

Profundice en los temas de investigación de 'Performance of electrochemical immunoassays for clinical diagnostics of SARS-CoV-2 based on selective nucleocapsid N protein detection: Boron-doped diamond, gold and glassy carbon evaluation'. En conjunto forman una huella única.

Citar esto